Cost-utility analysis for sublingual versus intravenous edaravone in the treatment of amyotrophic lateral sclerosis

Abstract Background Edaravone has been widely used in amyotrophic lateral sclerosis (ALS) treatment, and a sublingual (SL) tablet has been developed to offer a more convenient alternative for injection. We present a cost-utility analysis to comprehensively evaluate the costs and health outcomes of o...

Full description

Saved in:
Bibliographic Details
Main Authors: Chang Liu, Yao Wu, Fangxu Wang, Shuang Sun, Jiayin Wei, Libo Tao
Format: Article
Language:English
Published: BMC 2024-10-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-024-03381-w
Tags: Add Tag
No Tags, Be the first to tag this record!